Werkgroep Cardiologische centra Nederland English

SOCRATES-REDUCED (Klaar)

A randomized parallel-group, placebo-controlled, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with heart failure with reduced ejection fraction (HFrEF) suffering from worsening signs and symptoms of Heart Failure (HF) - SOluble guanylatguanylate Cyclase stimulatoR in heArT failurE patientS with REDUCED EF (SOCRATES-REDUCED)

Middel
BAY-1021189
Populatie
hartfalen
Fase
IIb
Jaar aanvang
2013

Contactpersoon

dr. J. Schaap (Cardioloog)
Breda, Amphia Ziekenhuis